Education
About Us
Working with TipRanks
Follow Us
Beta Bionics, Inc. (BBNX)
NASDAQ:BBNX
BBNX Stock Chart & Stats
$10.87
--
Market closed
$10.87
--
Day’s Range― - ―
52-Week Range$8.89 - $32.71
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.15M
Market Cap
$486.87M
Enterprise Value$462.50M
Total Cash (Recent Filing)$219.22M
Total Debt (Recent Filing)$7.30M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
May 12, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding44,382,145
10 Day Avg. Volume1,114,120
30 Day Avg. Volume1,150,634
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)4.29
Price to Sales (P/S)12.32
P/FCF Ratio0.00
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue4.61
Enterprise Value/Gross Profit8.33
Enterprise Value/Ebitda-7.32
Forecast
1Y Price Target
$22.89Price Target Upside110.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.76
Revenue Forecast (FY)$132.67M
Bulls Say, Bears Say
Bulls Say
Pipeline And Product RoadmapAnalyst notes progress on the development pipeline, including a planned patch pump and a bihormonal option, which could expand the addressable market and act as future growth catalysts.
Product Differentiation And AdoptionAnalyst highlights that the iLet system's differentiated closed‑loop algorithm and ease of use should attract patients and less‑experienced prescribers, enabling share gains from incumbents.
Profitability And Gross Margin ImprovementAnalyst reports gross margins exceeded expectations, reflecting a higher share of prescription patients and scale benefits that support improving profitability.
Bears Say
Regulatory And Quality RisksAnalyst warns an FDA warning letter citing safety‑reporting system deficiencies could require remediation efforts, attract competitor scrutiny, and increase compliance risk.
Rising Operating Costs And Margin PressureAnalyst notes planned sales force expansion and costs for new product configurations will raise operating and capital expenses relative to sales, which can pressure margins and increase cash burn.
Slowing Patient Starts And Market UptakeAnalyst cautions that flat or below‑expectation new patient starts and clinician survey responses indicating minimal prescription share gains raise concern about the company's ability to grow market share.
Beta Bionics, Inc. News
BBNX FAQ
What was Beta Bionics, Inc.’s price range in the past 12 months?
Beta Bionics, Inc. lowest stock price was $8.89 and its highest was $32.71 in the past 12 months.
What is Beta Bionics, Inc.’s market cap?
Beta Bionics, Inc.’s market cap is $486.87M.
When is Beta Bionics, Inc.’s upcoming earnings report date?
Beta Bionics, Inc.’s upcoming earnings report date is May 12, 2026 which is in 62 days.
How were Beta Bionics, Inc.’s earnings last quarter?
Beta Bionics, Inc. released its earnings results on Feb 17, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.403 by $0.103.
Is Beta Bionics, Inc. overvalued?
According to Wall Street analysts Beta Bionics, Inc.’s price is currently Undervalued.
Does Beta Bionics, Inc. pay dividends?
Beta Bionics, Inc. does not currently pay dividends.
What is Beta Bionics, Inc.’s EPS estimate?
Beta Bionics, Inc.’s EPS estimate is -0.49.
How many shares outstanding does Beta Bionics, Inc. have?
Beta Bionics, Inc. has 44,382,145 shares outstanding.
What happened to Beta Bionics, Inc.’s price movement after its last earnings report?
Beta Bionics, Inc. reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.403. Following the earnings report the stock price went down -2.577%.
Which hedge fund is a major shareholder of Beta Bionics, Inc.?
Currently, no hedge funds are holding shares in BBNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beta Bionics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$22.89 (110.58% Upside)
$22.89 (110.58% Upside)
Blogger Sentiment
Bullish
BBNX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 753.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $95.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.65%
12-Months-Change
Fundamentals
Return on Equity
-24.45%
Trailing 12-Months
Asset Growth
119.68%
Trailing 12-Months
Company Description
Beta Bionics, Inc.
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.
BBNX Company Deck
BBNX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong operational and commercial performance in 2025 — marked by substantial revenue growth (+54% YoY), accelerating user adoption (≈20,000 new users), improving gross margins (Q4 59%) and meaningful pipeline progress (Mint and bihormonal milestones). The company is well-capitalized ($265M) and has broadened PBM/pharmacy coverage. Key negatives include a recent FDA warning letter tied to quality systems and MDR timing (remediation in progress), materially higher operating expenses (+42% YoY in Q4), and short-term margin and seasonality headwinds related to pharmacy mix and Q1 cadence. Management reiterated confidence in remediation timelines and in their 2026 guidance, while opting for a deliberate sales force ramp and slightly reduced public granularity on new patient starts.View all BBNX earnings summariesBBNX Stock 12 Month Forecast
Average Price Target
$22.89
▲(110.58% Upside)
Technical Analysis
Labcorp Holdings
―
Tandem Diabetes Care
―
Envista Holdings
―
Sana Biotechnology
―
Fortrea Holdings Inc.
―
Ownership Overview
0.93% Insiders
12.81% Mutual Funds
61.62% Other Institutional Investors
15.46% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---